New cancer drug MRX-2843 enters first human trial

NCT ID NCT03510104

Completed Disease control Sponsor: Meryx, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRX-2843
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, not effectiveness. Many experimental cancer drugs fail to show benefit in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm metastatic neoplasm neoplasm Neoplasm Metastasis Neoplastic Processes Pathologic Processes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER METASTATIC CANCER NEOPLASM METASTASIS NEOPLASMS NEOPLASTIC PROCESSES PATHOLOGIC PROCESSES

Contacts and locations

Locations

Emory University

Atlanta, Georgia, 30322, United States
Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.